CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. - Archive ouverte HAL Access content directly
Journal Articles Transplantation Year : 2011

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.

(1, 2) , (1, 2) , (3) , (2, 3) , (1, 2)
1
2
3

Abstract

BACKGROUND: CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics. METHODS: We investigated the effect of CYP3A5 6986A>G polymorphism (CYP3A5*1/*3 alleles) on the pharmacokinetics of everolimus in 28 renal transplant patients and on its in vitro hepatic metabolism using a bank of genotyped human liver microsomes (n=49). We further evaluated in vitro the contribution of CYP3A4, CYP3A5, and CYP2C8 to everolimus hepatic metabolism using recombinant enzymes. RESULTS: We found no association between CYP3A5 polymorphism and everolimus pharmacokinetics in renal transplant patients. On the other hand, no effect of CYP3A5 polymorphism was observed on the intrinsic clearance of everolimus by human liver microsomes, whereas that of tacrolimus (positive control) was 1.5-fold higher in microsomes carrying the CYP3A5*1 allele than in noncarriers. In vitro data showed that CYP3A4 is a better catalyst of everolimus metabolism than CYP3A5, whereas the opposite was observed for tacrolimus. CONCLUSIONS: This study provides direct and indirect evidence that CYP3A5 genotyping cannot help improve everolimus therapy.
Fichier principal
Vignette du fichier
inserm-00542366_edited.pdf (249.68 Ko) Télécharger le fichier
Vignette du fichier
Manuscrit_CYP3A5_everolimus_Transplantation_.pdf (325.53 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00542366 , version 1 (30-03-2012)

Identifiers

Cite

Nicolas Picard, Koukeb Rouguieg-Malki, Nassim Kamar, Lionel Rostaing, Pierre Marquet. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.. Transplantation, 2011, 91 (6), pp.652-6. ⟨10.1097/TP.0b013e31820ae4ac⟩. ⟨inserm-00542366⟩
115 View
626 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More